PPARA and Hyperglycemia: Our results agree with Rieusset, since no evidence of decreased hyperglycemia or improvement in glucose tolerance in DB-rats, after a subchronic treatment with a selective PPARα agonist (fenofibrate) compared with CT-rats, was observed, suggesting that the cardioprotector effect is not due to glucose lowering effect.